Harmony Biosciences Holdings, Inc. Common Stock (HRMY) Stock Price

HRMYStock
$38.95+1.69%52W
Market Cap$2.27B
P/E14.22x
PEG Ratio
Div yield
Beta1.01

HRMY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-2.12%
Price vs S&P 500 (4W)4.58%
VGM Score67.60
P/E Ratio (Annual)14.22x

HRMY Earnings Surprise History

Q2 250.92est. 0.96
Q3 251.08est. 0.86
Q4 250.57est. 1.07
Q1 260.79est. 0.93
Q2 261.50est. 1.15

HRMY Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.76
3.76
3.76
3.81

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
HRMYHarmony Biosciences Holdings, Inc. Common Stock
BBC$38.95
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Harmony Biosciences Holdings, Inc. Common Stock

Harmony Biosciences is a pharmaceutical company commercializing therapies for rare neurological diseases with unmet medical needs. Its approved product WAKIX (pitolisant) treats cataplexy in narcolepsy patients through a novel H3 receptor mechanism. The company has multiple pipeline candidates targeting additional rare neurological conditions, positioning it in a specialized and underserved market segment.